Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Jan;39(1):71–76. doi: 10.1111/j.1365-2125.1995.tb04412.x

CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

E A Sotaniemi 1, A Rautio 1, M Bäckstrom 1, P Arvela 1, O Pelkonen 1
PMCID: PMC1364984  PMID: 7756103

Abstract

1. The in vitro hepatic metabolism of lignocaine to monoethylglycinexylide (MEGX) is mediated by CYP3A4 and that of coumarin to 7-hydroxycoumarin (7OHC) by CYP2A6. We investigated the usefulness of monitoring serum MEGX concentrations (after 1 mg kg-1 lignocaine i.v.) and urinary 7OHC excretion (after 5 mg coumarin p.o.) to reflect liver function in patients with liver (n = 36), kidney (n = 12) and epileptic (n = 12) disease and in control subjects (n = 20). The extent of liver disease was assessed using measurements of serum aminoterminal propeptide (PIIINP) and Child-Pugh grades. 2. Serum concentrations of MEGX were decreased in severe (4.6 +/- 3.0 s.d. ng ml-1), moderate (19.1 +/- 11.6 s.d. ng ml-1) and mild (32.8 +/- 14.2 s.d ng ml-1) liver disease as compared with controls (53.4 +/- 15.8 s.d ng ml-1). The excretion of 7OHC over 2 h was decreased in severe (18.0 +/- 10.3 s.d % of dose) and moderate (34.2 +/- 15.6 s.d %), but not in mild (49.7 +/- 19.0 s.d %) liver disease as compared with that in controls (56.2 +/- 11.6%). 3. In epileptic patients the urinary recovery of 7OHC was increased (2 h value 69.5 +/- 13.2 s.d %) suggesting enzyme induction. In contrast, serum MEGX concentration were low (40.0 +/- 14.1 s.d ng ml-1), possibly due to competition for CYP3A4 between lignocaine and antiepileptic drugs. 4. In patients with kidney disease serum MEGX concentration (56.5 +/- 26.1 s.d ng ml-1) was similar to that in controls.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
71

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bargetzi M. J., Aoyama T., Gonzalez F. J., Meyer U. A. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther. 1989 Nov;46(5):521–527. doi: 10.1038/clpt.1989.180. [DOI] [PubMed] [Google Scholar]
  2. Casini A., Ricci O. E., Paoletti F., Surrenti C. Immune mechanisms for hepatic fibrogenesis. T-lymphocyte-mediated stimulation of fibroblast collagen production in chronic active hepatitis. Liver. 1985 Jun;5(3):134–141. doi: 10.1111/j.1600-0676.1985.tb00228.x. [DOI] [PubMed] [Google Scholar]
  3. Chopra S., Griffin P. H. Laboratory tests and diagnostic procedures in evaluation of liver disease. Am J Med. 1985 Aug;79(2):221–230. doi: 10.1016/0002-9343(85)90013-0. [DOI] [PubMed] [Google Scholar]
  4. Clément B., Loréal O., Levavasseur F., Guillouzo A. New challenges in hepatic fibrosis. J Hepatol. 1993 Apr;18(1):1–4. doi: 10.1016/s0168-8278(05)80002-9. [DOI] [PubMed] [Google Scholar]
  5. Ged C., Rouillon J. M., Pichard L., Combalbert J., Bressot N., Bories P., Michel H., Beaune P., Maurel P. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol. 1989 Oct;28(4):373–387. doi: 10.1111/j.1365-2125.1989.tb03516.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hasselbalch H., Junker P., Hørslev-Petersen K., Lisse I., Bentsen K. D. Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy. Am J Hematol. 1990 Jan;33(1):18–26. doi: 10.1002/ajh.2830330105. [DOI] [PubMed] [Google Scholar]
  7. Leibovich S. J., Ross R. A macrophage-dependent factor that stimulates the proliferation of fibroblasts in vitro. Am J Pathol. 1976 Sep;84(3):501–514. [PMC free article] [PubMed] [Google Scholar]
  8. Oellerich M., Raude E., Burdelski M., Schulz M., Schmidt F. W., Ringe B., Lamesch P., Pichlmayr R., Raith H., Scheruhn M. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem. 1987 Dec;25(12):845–853. doi: 10.1515/cclm.1987.25.12.845. [DOI] [PubMed] [Google Scholar]
  9. Ohnhaus E. E., Breckenridge A. M., Park B. K. Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol. 1989;36(1):39–46. doi: 10.1007/BF00561021. [DOI] [PubMed] [Google Scholar]
  10. Olkkola K. T., Aranko K., Luurila H., Hiller A., Saarnivaara L., Himberg J. J., Neuvonen P. J. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993 Mar;53(3):298–305. doi: 10.1038/clpt.1993.25. [DOI] [PubMed] [Google Scholar]
  11. Orrego H., Medline A., Blendis L. M., Rankin J. G., Kreaden D. A. Collagenisation of the Disse space in alcoholic liver disease. Gut. 1979 Aug;20(8):673–679. doi: 10.1136/gut.20.8.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pirmohamed M., Allott R., Green V. J., Kitteringham N. R., Chadwick D., Park B. K. Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy. Br J Clin Pharmacol. 1994 Jun;37(6):577–581. doi: 10.1111/j.1365-2125.1994.tb04307.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Popper H., Uenfriend S. Hepatic fibrosis. Correlation of biochemical and morphologic investigations. Am J Med. 1970 Nov;49:707–721. doi: 10.1016/s0002-9343(70)80135-8. [DOI] [PubMed] [Google Scholar]
  14. Prockop D. J., Kivirikko K. I., Tuderman L., Guzman N. A. The biosynthesis of collagen and its disorders (first of two parts). N Engl J Med. 1979 Jul 5;301(1):13–23. doi: 10.1056/NEJM197907053010104. [DOI] [PubMed] [Google Scholar]
  15. Pugh R. N., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646–649. doi: 10.1002/bjs.1800600817. [DOI] [PubMed] [Google Scholar]
  16. Raunio H., Syngelmä T., Pasanen M., Juvonen R., Honkakoski P., Kairaluoma M. A., Sotaniemi E., Lang M. A., Pelkonen O. Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. Biochem Pharmacol. 1988 Oct 15;37(20):3889–3895. doi: 10.1016/0006-2952(88)90070-6. [DOI] [PubMed] [Google Scholar]
  17. Rautio A., Kraul H., Kojo A., Salmela E., Pelkonen O. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics. 1992 Oct;2(5):227–233. doi: 10.1097/00008571-199210000-00005. [DOI] [PubMed] [Google Scholar]
  18. Risteli J., Niemi S., Trivedi P., Mäentausta O., Mowat A. P., Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem. 1988 Apr;34(4):715–718. [PubMed] [Google Scholar]
  19. Rohde H., Vargas L., Hahn E., Kalbfleisch H., Bruguera M., Timpl R. Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest. 1979 Dec;9(6):451–459. doi: 10.1111/j.1365-2362.1979.tb00912.x. [DOI] [PubMed] [Google Scholar]
  20. SCHAFFNER F., POPER H. Capillarization of hepatic sinusoids in man. Gastroenterology. 1963 Mar;44:239–242. [PubMed] [Google Scholar]
  21. Saarni H. U., Savolainen E. R., Sotaniemi E. A. Effect of medroxyprogesterone acetate on liver collagen and drug metabolism in rats after chemical liver injury. Res Commun Chem Pathol Pharmacol. 1983 Oct;42(1):61–69. [PubMed] [Google Scholar]
  22. Shaw P. M., Barnes T. S., Cameron D., Engeset J., Melvin W. T., Omar G., Petrie J. C., Rush W. R., Snyder C. P., Whiting P. H. Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism. Biochem J. 1989 Nov 1;263(3):653–663. doi: 10.1042/bj2630653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Siegmund J. B., Wilson J. H., Imhoff T. E. Amiodarone interaction with lidocaine. J Cardiovasc Pharmacol. 1993 Apr;21(4):513–515. doi: 10.1097/00005344-199304000-00001. [DOI] [PubMed] [Google Scholar]
  24. Sotaniemi E. A., Ahlqvist J., Pelkonen R. O., Pirttiaho H., Luoma P. V. Histological changes in the liver and indices of drug metabolism in alcoholics. Eur J Clin Pharmacol. 1977 Apr 20;11(4):295–303. doi: 10.1007/BF00607680. [DOI] [PubMed] [Google Scholar]
  25. Sotaniemi E. A., Niemelä O., Risteli L., Stenbäck F., Pelkonen R. O., Lahtela J. T., Risteli J. Fibrotic process and drug metabolism in alcoholic liver disease. Clin Pharmacol Ther. 1986 Jul;40(1):46–55. doi: 10.1038/clpt.1986.138. [DOI] [PubMed] [Google Scholar]
  26. Wahl S. M., Wahl L. M., McCarthy J. B. Lymphocyte-mediated activation of fibroblast proliferation and collagen production. J Immunol. 1978 Sep;121(3):942–946. [PubMed] [Google Scholar]
  27. Waxman D. J., Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem J. 1992 Feb 1;281(Pt 3):577–592. doi: 10.1042/bj2810577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wrighton S. A., Ring B. J., Watkins P. B., VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol. 1989 Jul;36(1):97–105. [PubMed] [Google Scholar]
  29. Wrighton S. A., Stevens J. C. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992;22(1):1–21. doi: 10.3109/10408449209145319. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES